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Abstract
Erroneous assignments of clinical isolates to the interpretative categories susceptible, intermediate and resistant can deprive a patient of
successful antimicrobial therapy. The rate of major errors (ME) and very major errors (vME) is dependent on: (i) the precision/standard
deviation (r) of the antibiotic susceptibility testing (AST) method, (ii) the diameter distributions, (iii) clinical breakpoints, and (iv) the width
of the intermediate zone. The European Committee on AST (EUCAST) has abandoned or decreased the intermediate zone for several
drug/species combinations. This study focused on the effects of discontinuing the intermediate category on the rate of interpretation errors.
In total, 10 341 non-duplicate clinical isolates were included in the study. For susceptibility testing the disc diffusion method was used. Error
probabilities were calculated separately for diameter values ﬂanking the interpretative category borders. Error probabilities were then
applied to the actual numbers of clinical isolates investigated and expected rates of ME and vME were calculated. Applying EUCAST AST
guidelines, signiﬁcant rates of ME/vME were demonstrated for all drug/species combinations without an intermediate range. Virtually all ME/
vME expected were eliminated in CLSI guidelines that retained an intermediate zone. If wild-type and resistant isolates are not clearly
separated in susceptibility distributions, the retaining of an intermediate zone will decrease the number of ME and vME. An intermediate
zone of 2–3 mm avoids almost all ME/vME for most species/drug combinations depending on diameter distributions. Laboratories should
know their epidemiology settings to be able to detect problems of individual species/drug/clinical breakpoint combinations and take
measures to improve precision of diameter measurements.
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Introduction
The disc diffusion method was described by Bauer and Kirby in
the 1950s/1960s [1]. After more than 50 years, disc diffusion is
still a widely used procedure for antimicrobial susceptibility
testing (AST) in the clinical microbiological laboratory. National
and international guidelines refer to standardized Kirby–Bauer
testing, e.g. CLSI or European Committee on AST (EUCAST)
guidelines for AST [2,3]. Traditionally, the basis of clinical AST
reporting is categorization into susceptible (S), intermediate (I),
and resistant (R)—referring to the likelihood of clinical success
[4]. The susceptible category is deﬁned as likely therapeutic
success for the individual species/drug combination tested if
recommended standard dosing is applied [2,5]. The intermedi-
ate category is deﬁned as uncertain therapeutic success for the
individual species/drug combination tested by EUCAST and is
intended for compounds for which dosing can be increased.
CLSI deﬁnes the intermediate category as a lower response rate
than for susceptible isolates, but clinical efﬁcacy if the drug
accumulates at the site of infection. The intermediate category
represents the ‘grey zone’ regarding therapeutic success; it also
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helps to prevent serious categorization errors resulting from
imprecision of inhibition zone readings [4,6]. The resistant
category implies a high likelihood of therapeutic failure
(EUCAST) or no reliable clinical efﬁcacy (CLSI).
Differences in susceptibility categorization of individual
isolates in repeated or in parallel ASTs can be referred to as
‘discrepancies’. This statistical category is traditionally split for
AST interpretation according to the level of therapeutic
implications resulting from false categorization: Discrepancies
resulting in erratic assignment of bacterial isolates to adjacent
interpretative categories (S to I, I to S, I to R, R to I) are
referred to as ‘minor errors’ (mE) resulting in limited
therapeutic consequences [4,6,7]. Erroneous categorization
of true-susceptible isolates as resistant are referred to as
‘major errors’ (ME) leading to unnecessary restriction of
therapeutic options that can deprive a patient of a successful
therapy. The most serious clinical implications result from
‘very major errors’ (vME), i.e. categorization of true-resistant
isolates as susceptible—as a consequence there is a high
likelihood of therapeutic failure. Clinical isolates are often (i)
repeatedly tested for antimicrobial susceptibility to monitor
clinical course, therapeutic success, and the emergence of
resistance and (ii) grown and tested for antimicrobial suscep-
tibility from parallel samples of the same patient, bearing the
risk of discrepant and confusing AST reports.
The rates of ME and vME are dependent on: (i) the accuracy
of the AST method reﬂected by the standard deviation (r) of
measurements, and (ii) on the width of the intermediate zone. If
the intermediate zone is abandoned, the resistant and suscep-
tible categories become directly adjacent and all minor errors
will, by consequence, become ME and vME. EUCAST guidelines
have abandoned or decreased the intermediate zone for several
drug/species combinations (see Table 1). According to EUCAST
the intermediate category has been kept for drugs that can be
administered in high dose, but it has been abandoned for
compounds with only one approved dosing regimen. However,
there are several exceptions, e.g. for ciproﬂoxacin, ceftazidime,
or the aminoglycosides, variable dosing regimens are established
but no intermediate category is assigned. For other compounds,
e.g. amoxicillin-clavulanic acid, rationale documents for EUCAST
AST categories are currently not yet available [8,9]. As a result
EUCAST handling of the intermediate zone seems, in part,
inconsistent and incomprehensive from the outside. National
systems have adopted EUCAST clinical breakpoints (CBPs) and,
in part, abandoned or decreased the intermediate zones (British
Society for Antimicrobial Chemotherapy) [10]. In contrast,
other organizations have kept intermediate zones for all drugs
(CLSI) or retained the intermediate zone for more agents than
EUCAST (e.g. Comite de l’Antibiogramme de la Societe
Francaise de Microbiologie) [2,11].
The aim of this study was to calculate the expected rates of
ME and vME with the revised EUCAST and CLSI AST
guidelines for disc diffusion testing using a set of zone diameter
data generated with isolates of clinically important gram-
negative and gram-positive bacteria. The focus of this study
was on the effect of either discontinuing or downsizing the
intermediate category. Analyses were carried out for (i) a
statistically normalized setting (independent of an individual
epidemiological situation) and (ii) the actual epidemiological
situation of a clinical laboratory.
Materials and Methods
Bacterial strains
In total, 10 341 non-duplicate clinical isolates recovered in our
diagnostic laboratory during a period of 24 months from
January 2010 to December 2011 were included in the study,
comprising 2992 Escherichia coli, 317 Stenotrophomonas malto-
philia, 1610 Pseudomonas aeruginosa, 191 Acinetobacter bauman-
nii, 3001 Staphylococcus aureus and 2230 coagulase-negative
staphylococci. For some of the isolates not all zone diameter
values were available resulting in lower numbers of data points
for certain drug/species combinations (see Table 2).
Susceptibility testing
For susceptibility testing the disc diffusion method according
to Kirby–Bauer was used. Antibiotic discs were obtained from
Becton Dickinson (Franklin Lakes, NJ, USA). Susceptibility
testing was done on Mueller–Hinton agar (Becton Dickinson)
using McFarland 0.5 from overnight cultures followed by
incubation at 35°C for 16–18 h according to EUCAST
recommendations [3]. Inhibition zone diameters were deter-
mined using the semi-automated Sirweb/Sirscan system (i2a,
Montpellier, France).
Statistical analysis
Error probabilities were calculated separately for all diameter
values ﬂanking the interpretative category borders (S vs I, R vs
I, S vs R) covering a diameter range that comprised  95% of
all ME/vME expected. An example is shown in Fig. 1.
According to Altman et al. [12] normal distribution is a bell-
shaped, unimodal and symmetrical probability distribution. It is
described by two parameters, the mean (l) and the standard
deviation (r). The total area under the Gaussian density is
equal to 1. As a result of the symmetry, the probability for an
observation to be below the mean (l) is equal to the tail area
below the density to the left of the mean of the normal
distribution and is equal to 0.5. By similar argument the tail
area of the normal density to the right of the mean is equal to
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0.5. Any position along the horizontal x-axis can be expressed
as a distance of a number of standard deviations from the
mean. This distance is known as a standard normal deviate or
normal score. It is equivalent to looking at a normal
distribution with a mean 0 and a standard deviation 1, which
is called the standard normal distribution. The necessary
information for the lower and upper tail areas of the standard
normal distribution is readily available in statistical tables. See
for example table B1: Normal distribution—areas in one tail
(z->p) in Altman et al. [12]. It can also be computed by
TABLE 1. Clinical breakpoints and normalised error probabilities for European Committee for Antibiotic Susceptibility Testing
(EUCAST) and CLSI AST guidelines
Drug/species/group
Clinical breakpoints
Width of
intermediate
range (mm) Cumulated statistical probability (%) for ME/vME
CLSI EUCAST
CLSI EUCAST
r = 1 mm r = 2 mm r = 3 mm
S I R S I R CLSI EUCAST CLSI EUCAST CLSI EUCAST
Enterobacteriaceae
Ampicillin  17 14–16  13  14 <14 3 0 0.0015 9.1 1.5 13.9 8.6 15.7
Amoxicillin-clavulanic acid  18 14–17  13  17 <17 4 0 <0.0001 9.1 2.9 13.9 4.2 15.7
Piperacillin-tazobactam  21 18–20  17  20 17–19 <17 3 3 0.0015 0.0015 1.5 1.5 8.6 8.6
Cefuroxime  18 15–17  14  18 <18 3 0 0.0015 9.1 1.5 13.9 8.6 15.7
Cefoxitin  18 15–17  14  19 <19 3 0 0.0015 9.1 1.5 13.9 8.6 15.7
Cefpodoxime  21 18–20  17  21 <21 3 0 0.0015 9.1 1.5 13.9 8.6 15.7
Ceftriaxone  23 20–22  19  23 20–22 <20 3 3 0.0015 0.0015 1.5 1.5 8.6 8.6
Ceftazidime  21 18–20  17  22 19–21 <19 3 3 0.0015 0.0015 1.5 1.5 8.6 8.6
Cefotaxime  26 23–25  22  20 17–19 <17 3 3 0.0015 0.0015 1.5 1.5 8.6 8.6
Cefepime  18 15–17  14  24 21–23 <21 3 3 0.0015 0.0015 1.5 1.5 8.6 8.6
Meropenem  23 20–22  19  22 16–21 <16 3 6 0.0015 <0.0001 1.5 0.01 8.6 0.8
Imipenem  23 20–22  19  21 15–20 <15 3 6 0.0015 <0.0001 1.5 0.01 8.6 0.8
Ertapenem  23 20–22  19  25 20–24 <20 3 5 0.0015 <0.0001 1.5 0.1 8.6 1.9
Tobramycin  15 13–14  12  16 14–15 <14 2 2 0.07 0.07 4.9 4.9 16.0 16.0
Amikacin  17 15–16  14  16 14–15 <14 2 2 0.07 0.07 4.9 4.9 16.0 16.0
Gentamicin  15 13–14  12  17 15–16 <15 2 2 0.07 0.07 4.9 4.9 16.0 16.0
Ciproﬂoxacin  21 16–20  15  22 19–21 <19 5 3 <0.0001 0.0015 0.1 1.5 1.9 8.6
Levoﬂoxacin  17 14–16  13  22 19–21 <19 3 3 0.0015 0.0015 1.5 1.5 8.6 8.6
Norﬂoxacin  17 13–16  12  22 19–21 <19 4 3 <0.0001 0.0015 2.9 1.5 4.2 8.6
Trimethoprim-
Sulfamethoxazole
 16 11–15  10  16 13–15 <13 5 3 <0.0001 0.0015 0.1 1.5 1.9 8.6
Stenotrophomonas maltophilia
Trimethoprim-
sulfamethoxazolexazole
 16 11–15  10  16 <16 5 0 <0.0001 9.1 0.1 13.9 1.9 15.7
Pseudomonas aeruginosa
Piperacillin-tazobactam  21 15–20  14  19 <19 6 0 <0.0001 9.1 13.9 15.7
Ceftazidime  18 15–17  14  16 <16 3 0 0.0015 9.1 1.5 13.9 8.6 15.7
Cefepime  18 15–17  14  18 <18 3 0 0.0015 9.1 1.5 13.9 8.6 15.7
Imipenem  16 14–15  13  20 18–19 <18 2 2 0.07 0.07 4.9 4.9 16.0 16.0
Meropenem  16 14–15  13  24 18–23 <18 2 6 0.07 <0.0001 4.9 0.01 16.0 0.8
Tobramycin  15 13–14  12  16 <16 2 0 0.07 9.1 4.9 13.9 16.0 15.7
Amikacin  17 15–16  14  18 15–17 <15 2 3 0.07 0.0015 4.9 1.5 16.0 8.6
Gentamicin  15 13–14  12  15 <15 2 0 0.07 9.1 4.9 13.9 16.0 15.7
Ciproﬂoxacin  21 16–20  15  25 20–24 <20 5 5 <0.0001 <0.0001 0.1 0.1 1.9 1.9
Levoﬂoxacin  17 14–16  13  20 17–19 <15 3 3 0.0015 0.0015 1.5 1.5 8.6 8.6
Acinetobacter baumannii
Imipenem  16 14–15  13  23 18–22 <18 2 5 0.07 <0.0001 4.9 0.1 16.0 1.9
Meropenem  16 14–15  13  21 16–20 <16 2 5 0.07 <0.0001 4.9 0.1 16.0 1.9
Tobramycin  15 13–14  12  17 <17 2 0 0.07 9.1 4.9 13.9 16.0 15.7
Amikacin  17 15–16  14  18 16–17 <16 2 2 0.07 0.07 4.9 4.9 16.0 16.0
Gentamicin  15 13–14  12  17 <17 2 0 0.07 9.1 4.9 13.9 16.0 15.7
Ciproﬂoxacin  21 16–20  15  21 <21 5 0 <0.0001 9.1 0.1 13.9 1.9 15.7
Levoﬂoxacin  17 14–16  13  21 19–20 <19 3 2 0.0015 0.07 1.5 4.9 8.6 16.0
Staphylococcus aureus
Cefoxitin  22  21  22 <22 0 0 9.1 9.1 13.9 13.9 15.7 15.7
Tobramycin  15 13–14  12  18 <18 2 0 0.07 9.1 4.9 13.9 16.0 15.7
Amikacin  17 15–16  14  18 16–17 <16 2 2 0.07 0.07 4.9 4.9 16.0 16.0
Gentamicin  15 13–14  12  18 <18 2 0 0.07 9.1 4.9 13.9 16.0 15.7
Coagulase-negative
staphylococci
Cefoxitin  25  24  25 <25 0 0 9.1 9.1 13.9 13.9 15.7 15.7
Tobramycin  15 13–14  12  22 <22 2 0 0.07 9.1 4.9 13.9 16.0 15.7
Amikacin  17 15–16  14  22 19–21 <19 2 3 0.07 0.0015 4.9 1.5 16.0 8.6
Gentamicin  15 13–14  12  22 <22 2 0 0.07 9.1 4.9 13.9 16.0 15.7
Staphylococci (general)
Penicillin  29  28  26 <26 0 0 9.1 9.1 13.9 13.9 15.7 15.7
Levoﬂoxacin  19 16–18  15  22 20–21 <19 3 2 0.0015 0.07 1.5 4.9 8.6 16.0
Erythromycin  23 14–22  13  21 19–20 <18 9 2 <0.0001 0.07 <0.0001 4.9 <0.0001 16.0
Clindamycin  21 15–20  14  22 19–21 <19 6 3 <0.0001 0.0015 0.01 1.5 0.8 8.6
Rifampicin  20 17–19  16  26 23–25 <23 3 3 0.0015 0.0015 1.5 1.5 8.6 8.6
Trimethoprim-
Sulfamethoxazole
 16 11–15  10  17 14–16 <14 5 3 <0.0001 0.0015 0.1 1.5 1.9 8.6
S, susceptible; I, intermediate; R, resistant; r, standard deviation; ME, major error; vME, very major error.
Statistical probabilities were calculated on the basis of standard deviations of 1 2, and 3 mm in disc diffusion readings assuming equal numbers of isolates for all diameter values, i.e.
independent of the epidemiological situation present. The cumulated statistical probability comprises  95% of all possible ME/vME.
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statistical packages such as the freely available R (http://www.r-
project.org/). The normality assumption is useful in describing
real-world data. In particular it is well known that laboratory
measurements are not exact. One possible assumption is that
the true unknown diameter is normally distributed around the
mean diameter obtained by the Kirby–Bauer method with a
given r. When a set of observations has a distribution that is
similar to a normal distribution it can be assumed that in the
population the distribution of the variable is normal and
calculations can be carried out on this basis, as suggested by
Altman et al. [12]. The assumed probability distribution can be
used to calculate the theoretical upper and lower tail areas
with respect to different cut-offs (see Fig. 1). In such a case the
normal distribution is a theoretical equivalent of the empirical
relative frequency distribution.
In the ﬁrst step of this study the theoretical tail areas
exceeding the clinical breakpoints for different l and r
scenarios were calculated by setting standard deviation (r)
to r = 1 mm, r = 2 mm, or r = 3 mm (Fig. 1). In a second
step, to estimate the relevance of the erroneous classiﬁcations
for laboratory practice, the expected absolute frequencies of
erroneously classiﬁed measurements were computed for the
given observed populations. To calculate 95% CI for error
probabilities, Wilson’s method was used [13].
Standard deviations of disc diffusion inhibition zones for
individual drug/species combinations were calculated from 19
independent readings by 19 experienced persons under
standardized ambient conditions (EUCAST recommended)
using E. coli ATCC 25922, S. aureus ATCC 29213, P. aerugin-
osa ATCC 27853, and two clinical strains of A. baumannii and
Stenotrophomonas maltophilia with a resistance pattern consis-
tent with that of the wild type [3].
Software
All calculations were done using the IBM SPSS statistics
software version 20 (IBM Corporation, Armonk, NY, USA),
the MICROSOFT EXCEL 2010 software (Microsoft Corporation,
Redmond, WA, USA), and the software R (freely available
under http://www.r-project.org/).
Results
Calculation of expected error rates independent of diameter
distributions
In a ﬁrst step, cumulated statistical probabilities for ME and
vME were calculated for r = 1 mm, r = 2 mm and r = 3 mm,
normalized to equal numbers of isolates for each diameter
value, i.e. error rates for the  95% probability range of ME/
vME were calculated independently of actual isolate numbers
in diameter distributions. Cumulated statistical probabilities
for ME and vME signiﬁcantly increased for drugs without an
intermediate range: depending on the value of r, cumulated
probabilities of ME/vME ranged from 9.1% (r = 1 mm) to
15.7% (r = 3 mm) when no intermediate zone was deﬁned
(see Table 1). An intermediate zone of 2 mm resulted in
(b)(a)
FIG. 1. Principle of the calculation of statistical error probabilities. The diagrams illustrate the calculation principle of error probabilities. European
Committee for Antibiotic Susceptibility Testing resistant and susceptible category ranges are indicated above the diameter scale. Example (a) The
actually measured diameter value (black arrow) is 15 mm (resistant). The probability for this measurement to represent a major error (ME; false-
resistant) equals the probabilities for all diameter values in the susceptible category to be the—per deﬁnition unknown—true value. Probabilities can
be assumed to be normally distributed, depending on the standard deviation (r) of measuring. Assuming the true value (white arrow) is 17 mm
(susceptible), the ME (false-resistant) probability is equal to the upper tail probability (i.e. upper tail area under the curve for the multiples of r at
17 mm, black shaded). For example, if the r is 1 mm, the probability that the true value is 17 mm is equal to 0.0222, i.e. 2.2%. In this example the
probability that the actually measured value of 15 mm represents an ME is 2.2%. Example (b) Given an actually measured value of 17 mm (susceptible,
black arrow), and a r of 1 mm, the probability that the—unknown—true value (white arrow) is 16 mm (i.e. the actual measurement of 17 mm would
be a false-susceptible result, very major error (vME)) is equal to 0.1587, i.e. 15.87% (lower tail area under the curve for the multiples of r at 16 mm,
black shaded). r, standard deviation.
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cumulated ME/vME probabilities of 0.07–15.7% depending on
r. Most intermediate zones as deﬁned by EUCAST and CLSI
comprise a range of 3 mm, resulting in cumulated ME/vME
probabilities of 0.0015–8.6% depending on r (Table 1).
Calculation of expected error rates applying individual
diameter distributions
Further calculations on error rates applying the diameter
distributions as determined in the clinical laboratory were
performed for those drug/species combinations with the
highest statistical probabilities for ME and vME, i.e. for those
combinations lacking an intermediate range in EUCAST and
CLSI CBP tables (Table 1, bold numbers). Results for individual
drug/species combinations are summarized below.
Escherichia coli
The cumulated ME/vME rate for ampicillin, amoxicillin-clavul-
anic acid, cefuroxime and cefoxitin according to EUCAST
CBPs ranged from 8% to 14% for isolates included in the
 95% probability range for ME/vME (Table 2). The highest
absolute number of expected errors was calculated for
amoxicillin-clavulanic acid (n = 63 errors in 655 isolates at
risk). The high number of isolates at risk was caused by a
unimodal diameter distribution that showed a shoulder
towards smaller diameter values (Fig. 2). Values of ME and
vME were almost equally distributed except for cefpodoxime
for which 18% ME and 82% vME were expected. The majority
of isolates in the  95% probability range for ME/vME was
situated in the lower third of the wild-type distribution curve
(Fig. 2). CLSI has kept intermediate zones for all drugs
resulting in error rates <0.01% with no ME/vME to be
expected in the present population of isolates at risk (95%
probability level of ME/vME).
Stenotrophomonas maltophilia
The cumulated rate of expected ME/vME for trimethoprim-
sulfamethoxazole and EUCAST CBPs was 9%. The absolute
number of isolates with errors was comparably low (n = 3).
The cumulated ME/vME rate for trimethoprim-sulfamethoxaz-
ole applying CLSI CBPs was <0.01% (n = 0).
Pseudomonas aeruginosa
Applying EUCASTCBPs resulted in cumulatedME/vME rates for
piperacillin-tazobactam, ceftazidime, cefepime, tobramycin and
gentamicin of 2–7% for isolates in the 95% probability range for
ME/vME. The relation of ME and vME was almost equal with a
slight tendency to more vME for cefepime, tobramycin and
piperacillin-tazobactam (ME/vME relations of 41/59%, 33/67%
and 40/60%, see Table 2). If applying theCLSI CBPs, noME/vMEs
were expected (Table 2). The  95% probability range for ME/
vME ﬂanking EUCAST CBPs comprised signiﬁcant parts of the
diameter distribution curves for piperacillin-tazobactam, cefe-
pime, tobramycin and gentamicin (Fig. 2). Notably, EUCAST
CBPs for piperacillin-tazobactam, cefepime and gentamicin
divided the wild-type population (Fig. 2).
Acinetobacter baumannii
For tobramycin, gentamicin and ciproﬂoxacin cumulated ME/
vME rates in the EUCAST system were 29%, 6% and 18%,
respectively. For ciproﬂoxacin the expected ME/vME relation
was shifted towards vME (ratio ME/vME 33/67%, Table 2). If
applying the CLSI CBPs no ME/vME were expected (Table 2).
Staphylococcus aureus
Applying EUCAST CBPs cumulated ME/vME rates ranged from
2% to 4% for isolates in the 95% ME/vME probability range for
cefoxitin, tobramycin and gentamicin. In the case of gentamicin,
more expected ME than vME were calculated (67% vs 33%,
Table 2). Regarding cefoxitin, expected ME/vME rates using
CLSI guidelines equalled those applying EUCAST guidelines.
Tobramycin and gentamicin calculations showed no expected
ME/vME applying CLSI CBPs; the  95% probability range for
ME/vME adjacent to EUCAST CBPs comprised low numbers of
isolates (see Table 2, Fig. 2).
Coagulase-negative staphylococci
When applying EUCAST CBPs, cumulated ME/vME rates for
cefoxitin, tobramycin and gentamicin ranged from 6% to 12%
for isolates in the 95% ME/vME probability range. For cefoxitin
slightly more expected vME than ME were calculated (60% vs
40%, Table 2). Regarding cefoxitin, the expected ME/vME rates
using CLSI guidelines equalled those for EUCAST guidelines.
With tobramycin and gentamicin no ME/vME were expected
applying CLSI CBPs. Distribution curves showed that wild-type
and tobramycin and gentamicin resistant populations were not
clearly separated because of the formation of a ‘transition
population’ (Fig. 2).
All staphylococci (Staphylococcus aureus and coagulase-
negative staphylococci)
The rate of expected ME/vME applying EUCAST CBPs for
penicillin G was 1% for isolates at risk (95% probability level of
ME/vME, Table 2). However, the absolute number of errors
was low (n = 1) because few clinical isolates showed diameter
values in the 95% probability range of ME/vME (see Fig. 2). For
penicillin G, wild-type and resistant populations were clearly
separated (Fig. 2). Error rates in the CLSI system could not be
determined for penicillin G because data were only available
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E. coli
FIG. 2. Diameter distributions, European Committee for Antibiotic Susceptibility Testing (EUCAST) clinical breakpoints, and probability ranges of
 95% for major error/very major error (ME/vME). Diameter distributions are displayed for species/drug combinations with high probabilities of ME/
vME (see Table 1, bold numbers). EUCAST clinical breakpoints are indicated by black lines, borders of the  95% probability range for ME/vME are
indicated by dotted lines.
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S. maltophilia
P. aeruginosa
FIG. 2. Continued.
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A. baumannii
FIG. 2. Continued.
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for the EUCAST recommended disc content (1 lg/disc
EUCAST vs 10 lg/disc CLSI).
S. aureus CoNS
FIG. 2. Continued.
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E59–E71
E68 Clinical Microbiology and Infection, Volume 19 Number 2, February 2013 CMI
Discussion
The deﬁnition of CBPs is a complex process integrating
epidemiological cut-off (ECOFF) values from MIC distribu-
tions, correlating these ECOFFs to zone diameters in a
scattergram, and subsequently relating the putative CBPs to
pharmacokinetic (PK)/pharmacodynamic (PD) data. The
ﬁnal step is validation of proposed CBPs from
ECOFF and PK/PD data by means of clinical outcome
studies [4].
Several methods can be used to deﬁne CBPs on the basis of
disc diffusion, e.g. normalized resistance interpretation, the
classical error-rate-bounded method, modiﬁcations of the
error-rate-bounded method, or detailed modelling of the
spread of errors [4,6,7,14–17]. CLSI uses a variant of the
error-rate-bounded method, incorporating an intermediate
zone that inﬂuences the rate of mE, ME and vME [14].
EUCAST deﬁnes harmonized MIC CBPs on the basis of
ECOFFs and PK/PD parameters and correlates MIC CBPs to
zone diameter values using the ‘MIC-coloured zone diameter
histogram technique’ [16,18]. EUCAST has, in part, abandoned
the intermediate category with the view to facilitate AST
interpretation and to avoid splitting wild-type populations
referring to PK/PD data. Concomitantly, CBPs for drug/species
combinations without an intermediate zone relate to high-
dose therapy only [8]. Abandoning or decreasing the inter-
mediate zone that had in the past been established to decrease
the rate of ME and vME in AST interpretation runs the risk of
an increased frequency of interpretative errors and may result
in so-called type I errors [6,19]. As a consequence, serious
treatment failures may result from false categorization. In the
case of extended spectrum b-lactamase producers EUCAST
and CLSI proposed clinical categorization based on AST
readings alone—independent of whether the mechanism itself
is present [2,9]. This strategy poses a paradigm change as
interpretative reading is abandoned and diameter (or MIC)
testing alone becomes the single parameter to predict clinical
outcome [20]. Adopting such a strategy must be accompanied
by ensuring the most accurate and reproducible S/I/R catego-
rization because otherwise serious treatment errors may
result from measurement inaccuracy [21].
The number of ME and vME depends on several variables: (i)
the presence of an intermediate zone; (ii) the shape of
diameter distribution curves; and (iii) the precision of
measurements.
The presence and width of an intermediate zone are critical
for the rate of ME/vME [4,6]. Examples for the inﬂuence of an
intermediate zone with several drugs are the error probabil-
ities shown in Tables 1 and 2.
The absolute number of isolates with diameter measure-
ments adjacent to R/S CBPs, and so the absolute number of
errors, is dependent on the shape of the diameter distribution
curves. For clearly separated wild-type and resistant popula-
All staphylococci
FIG. 2. Continued.
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tions the setting of an S/R CBP at the ECOFF produces low
numbers of ME and vME as few isolates cluster around the
CBP (e.g. penicillin G and staphylococci, Table 2, Fig. 2). If,
however, the wild-type is not clearly separated from the
resistant population the number of errors increases as more
isolates cluster around the CBP (e.g. diameter distribution of
amoxicillin-clavulanic acid in E. coli, Table 2, Fig. 2). To address
this problem, the separation of wild-type and resistant
populations by determination of the optimal disc content for
a speciﬁc species/drug combination has been suggested
[22,23].
Setting the CBP equal to the ECOFF encloses part of the
wild-type population in the  95% probability range for ME/
vME, inevitably leading to ME. In contrast, setting the CBP
close to a resistant population would avoid ME, but increase
the probability for vME. Increasing the S/R zone diameter
breakpoint above the ECOFF would avoid vME, but split
the wild-type population between different categories
[16,18,24].
The relation of ME to vME in a clinical laboratory depends
on the individual diameter distributions (see Fig. 2). Three
basic scenarios are possible: (i) diameter measurements of
isolates included in the  95% ME/vME range are evenly
distributed resulting in equal numbers of expected ME and vME
(e.g. tobramycin and S. aureus, and amoxicillin-clavulanic acid
and E. coli, Table 2, Fig. 2); (ii) more measured diameter values
are greater than the S/R breakpoint, i.e. categorized suscep-
tible leading to higher numbers of vME (e.g. cefpodoxime and
E. coli, ciproﬂoxacin and A. baumannii, or tobramycin and
P. aeruginosa, Table 2, Fig. 2); (iii) more measured diameter
values are lower than the S/R breakpoint, i.e. categorized
resistant and the probability for ME is relatively increased (e.g.
gentamicin and S. aureus, see Table 2, Fig. 2).
The critical inﬂuence of an individual epidemiological
situation (reﬂected in the shape of a diameter distribution
curve) is illustrated by tobramycin and P. aeruginosa. The
EUCAST diameter distribution shows a low number of isolates
with diameters of 14–17 mm (95% ME/vME probability range).
The CBP (16 mm) is equal to the ECOFF [25]. In our study
population, however, a signiﬁcant number of isolates showed
inhibition zones of 14–17 mm (n = 100 out of 1604, i.e. 6.2%
of all P. aeruginosa isolates in this study). The resulting ME/vME
rate of 3% was comparably low because of a low r of 0.5 mm.
In-depth analysis of these isolates showed that a signiﬁcant
proportion (44.1%, corrected for duplicates) originated from
patients in the cystic ﬁbrosis or lung transplantation unit where
tobramycin is a mainstay drug. Recording zone diameters will
give laboratories information about their local epidemiology,
which inﬂuences error rates. Local adaptations of general
breakpoints will be facilitated, a strategy that was repeatedly
recommended to improve correct assignment of strains to
interpretative categories [16,24,26–29].
The precision of diameter measurements as reﬂected by r
signiﬁcantly inﬂuences the number of ME/vME (see Table 1).
r is itself dependent on factors like inoculum, agar compo-
sition, disc content or incubation time, in addition to intra-
person and inter-person variances: the higher the value of r,
the broader the  95% ME/vME probability range: e.g. in the
present study r for cefpodoxime and E. coli was 2.4 mm
resulting in an interval of 10 mm containing  95% of all ME/
vME vs ampicillin with r = 1.2 mm resulting in an interval
width of 4 mm (see Table 2 and Fig. 2). The inﬂuence of r
on error rates is best illustrated by r mean values as
determined for E. coli and P. aeruginosa isolates in this study
(r = 1.5 mm vs r = 0.8 mm for E. coli and P. aeruginosa,
respectively, as determined from r values listed in Table 2).
These values of r result in mean ME/vME rates of 12% in
E. coli vs 5% in P. aeruginosa. The error rates used for
calculations in this work may even be underestimated as
factors like inoculum, agar composition, disc content or
incubation time (standardized in the present work) addition-
ally contribute to r besides inter-person variance. EUCAST
accepts quality control ranges of 5–10 mm for individual
drug/species combinations. Assuming that this reﬂects a range
of  2*r, the accepted one-fold r range is from 1.25 to
2.5 mm. Separation of resistant and wild-type isolates by
CBPs can be ensured by taking into account r and associated
error probability ranges. Hence, the width of the interme-
diate category represents the measurement inaccuracy.
The assumption of normality is one possible approximation
to reality but frequently a reasonable one. Our study
demonstrates the consequences of removing the intermediate
zone and illustrates challenges, difﬁculties and problems
attached to the setting of CBPs. Although the problem of
reporting ME and vME is apparently limited to a comparably
small part of the population (highest cumulated ME/vME rate of
3.1% for tobramycin in A. baumannii relating to the complete
study population, see Table 2), the reliable classiﬁcation of
isolates in the  95% ME/vME probability range (close to
CBPs) is of vital importance for clinical decisions and
monitoring therapeutic success.
Four conclusions can be drawn from this study. (i) If the
wild-type is not clearly separated from the resistant population
an intermediate or ‘grey’ zone should be kept, decreasing ME/
vME numbers. Assigning isolates with uncertain classiﬁcation
to an intermediate category avoids producing a feigned
impression of precision in AST classiﬁcation. This will prevent
confusion of clinicians receiving discrepant (S/R) results for
isolates with true diameter values close to the CBPs originat-
ing from parallel samples or from samples that are tested
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consecutively for monitoring therapeutic success. (ii) An
intermediate zone of at least 2–3 mm avoids almost all ME/
vME for most species/drug combinations (Table 1). (iii)
Laboratories should know their individual diameter distribu-
tions to detect problems with individual species/drug/CBP
combinations. (iv) Clinical microbiologists should be aware of
the individual drug/r combinations in their laboratories to
monitor the precision of diameter measurements. Measures
should be taken to decrease r of diameter measurements and
enhance reproducibility, e.g. by training of personnel or by
automation of diameter measurements.
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